Agenus Inc. AGEN

LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Agenus now carries an updated implied fair value of about US$26.33 per share, up from US$19.50, which reflects a change of roughly 35% in the price target used in this analysis. Recent Street commentary links these higher targets to the botensilimab plus balstilimab program in microsatellite stable colorectal cancer and to fresh capital that affects how investors think about financing risk. Read on to see how this evolving narrative around Agenus could matter for your own view of the...